Project Oncology-logo

Project Oncology

ReachMD

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.
More Information

Location:

Fort Washington, PA

Networks:

ReachMD

Description:

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.

Language:

English


Episodes

Investigating Plinabulin for Prevention of Chemotherapy-Induced Neutropenia

8/4/2017
More
Host: Matt Birnholz, MD Guest: Douglas W. Blayney, MD, FACP Severe neutropenia is a dangerous potential complication of myelosuppressive chemotherapy, which exposes patients to high risks of infections and can result in death. Dr. Douglas W. Blayney, oncologist and Professor of Medicine at the Cancer Institute of Stanford University School of Medicine, joins host Dr. Matt Birnholz, to discuss a phase 2 of 3 clinical research trial, which is investigating the role of plinabulin for...

Duration: 00:16:59


Immuno-Oncology: Perspectives on Current Therapies & Future Developments

6/8/2017
More
Guest: Ezra E.W. Cohen, MD Guest: James L. Gulley, MD, PhD, FACP Guest: Omid Hamid, MD Guest: Howard L. Kaufman, MD, FACS Guest: Kunle Odunsi, MD, PhD, FRCOG, FACOG Guest: Mario Sznol, MD This program presents several expert perspectives on the latest immuno-oncology developments and how these advancements are impacting clinical practice. This program has been developed with funding from EMD Serono, Inc. and Merck KGaA, Darmstadt, Germany.

Duration: 00:14:29


Investigating Plinabulin as Immune-Modifying Therapy for Non-Small Cell Lung Cancer (NSCLC)

5/26/2017
More
Host: Matt Birnholz, MD Guest: Alain Mita, MD, MSc Each year more people die of lung cancer than of colon, breast, and prostate cancers combined. Non-small cell lung cancer, which accounts for 85% of lung cancer cases, has been the key target of several clinical trials evaluating new immune-modifying agents. Dr. Alan Mita, Associate Professor of Medicine and Co-Director of Experimental Therapeutics at the Samuel Oschin Comprehensive Cancer Institute of Cedar Sinai Medical Center in Los...

Duration: 00:14:59


Pancreatic Cancer: Associated Signs, Symptoms, Risk Factors and Treatment Approaches

5/23/2017
More
Host: Jennifer Caudle, DO Guest: Major Kenneth Lee, IV, MD, PhD Though a relatively rare disease, pancreatic cancer remains at the forefront of clinical discussion due to its highly aggressive nature. Dr. Major Kenneth Lee, Assistant Professor of Surgery at Penn Medicine, estimates that pancreatic cancer will become the number 2 cause of cancer death by the year 2020. This projected rise in mortality is largely due to the need for better advancement in treatment options. Join host Dr....

Duration: 00:17:59


Advances in the Treatment of Glioblastoma Multiforme: Is There a Role for Immune Checkpoint Inhibitors?

3/17/2017
More
Host: Brian P. McDonough, MD, FAAFP Guest: Michael Lim, MD Despite significant progress in the treatment for glioblastoma multiforme, or GBM, patient outcomes have failed to see a drastic improvement. Recently, immune checkpoint inhibitors have shown promise in treating patients with GBM in cases where conventional treatment options have failed. The rapid progression of GBM necessitates timely and well-informed decisions made on the part of the clinician. This activity will provide the...

Duration: 00:21:59


Hot Topics in Breast Cancer Innovations

2/6/2017
More
Host: Matt Birnholz, MD Guest: Ari Brooks, MD Guest: Brian Englander, MD Host Dr. Matt Birnholz is joined by Dr. Ari Brooks, Director of Endocrine and Oncology Surgery and Director of the Integrated Breast Center at Pennsylvania Hospital, and Dr. Brian Englander, Clinical Assistant Professor and Chair of the Department of Radiology at Pennsylvania Hospital. Drs. Brooks and Englander discuss the hot topics within breast cancer innovations. They touch upon the increase in involvement of...

Duration: 00:19:30


Current Best Practices in the Management of Thyroid Nodules and Cancer

1/31/2017
More
Guest: Sanziana Roman, MD, FACS CME Information FacultySanziana Roman, MD, FACSProfessor of SurgerySection of Endocrine SurgeryDepartment of SurgeryAssociate Chief, Division of Advanced Oncologic and GI SurgeryDuke University Medical CenterDurham, NC Activity PlannersChristie Avraamides, PhDClinical Content ManagerMed-IQBaltimore, MD Rebecca L. Julian, MS, ELSSenior Managing EditorMed-IQBaltimore, MD Amy SisonDirector of Continuing Medical EducationMed-IQBaltimore, MD WriterKatherine A....

Duration: 00:40:30


Selecting the Optimal Treatment for Brain Metastases

1/31/2017
More
Guest: John Kirkpatrick, MD, PhD Guest: John Sampson, MD, PhD, MHSC, MBA CME Information FacultyJohn Kirkpatrick, MD, PhD Associate Professor of Radiation Oncology and SurgeryDuke University Health System Durham, NC John Sampson, MD, PhD, MHSC, MBARobert H. Wilkins and Gloria Wilkins Professor of NeurosurgeryChair, Department of NeurosurgeryDuke University Health System Durham, NC Activity PlannersMeghan Coulehan, MPHManager, Educational Strategy and ContentMed-IQBaltimore, MD Amy...

Duration: 00:41:59


Highlights from the 17th Annual IASLC World Conference on Lung Cancer: International Focus on Emerging Advances in NSCLC Management

12/21/2016
More
Host: Jennifer Caudle, DO Guest: Edward B. Garon, MD, MS Based on CDC data, lung cancer represents 13% of all cancers diagnosed worldwide, and 19% of all cancer deaths. With almost 225,000 cases and more than 158,000 deaths anticipated in 2016 in the United States alone, lung cancer is the leading cause of cancer-associated mortality. Non-small cell lung cancer represents approximately 85% of those cases, which makes the need to better identify and treat this disease a critical need....

Duration: 00:18:00


Highlights from the 13th International Congress of the Society for Melanoma Research: A Focus on Resistance

11/28/2016
More
Host: Barnett Mennen, MD Guest: Meenhard Herlyn, DVM, DSc Melanomas are among the most genetically abnormal malignancies with hundreds or even thousands of mutations. In this activity, Dr. Meenhard Herlyn discusses updates on resistance from the 13th International Congress of the Society for Melanoma Research that took place recently in Boston, Massachusetts. Topics include, therapy strategies that benefit from many mutations, how melanomas adapt to growth outside of the human host, and...

Duration: 00:19:29


Highlights from the 13th International Congress of the Society for Melanoma Research: A Focus on Checkpoint Inhibition

11/23/2016
More
Host: Barnett Mennen, MD Guest: Michael Postow, MD Immunotherapy, notably overcoming checkpoint inhibition, has become an integral part of treatment for melanoma, if not a growing list of other cancers. In this activity, Dr. Michael Postow discusses major updates on the use of immunotherapy in melanoma as presented at the 13th International Congress of the Society for Melanoma Research that took place recently in Boston, Massachusetts. Topics include the general mechanistic principles...

Duration: 00:16:59


Panel Discussion: Impact of Extended HPV Genotype Testing on Current Cervical Cancer Algorithms

5/31/2016
More
Guest: Warner K. Huh, MD Guest: Thomas C. Wright, Jr., MD HPV experts, Drs. Warner Huh and Tom Wright discuss the potential of extended HPV genotype testing in high-risk HPV screening for cervical cancer, and the impact that this may have on the current cervical cancer algorithms.

Duration: 00:29:30


An Introduction to Next Generation Sequencing

2/25/2016
More
Guest: Carl D. Morrison, MD, DVM In this segment, Dr. Morrison will discuss how Next Generation Sequencing (NGS) is a sound technological process with highly accurate results as well as describe the NGS annotation process, including relevant questioning. This activity is the fifth in a series of eight in-depth discussions with oncology thought leaders at the Roswell Park Cancer Institute in Buffalo, New York, targeting Primary Care and Family physicians. This series was made possible...

Immunotherapy for Lung Cancer: The Present and the Future

2/10/2016
More
Guest: Suresh S. Ramalingam, MD In this discussion, Dr. Ramalingam will assess the value offered by checkpoint inhibitors in the treatment of NSCLC, alone and in combination with chemotherapy and how to incorporate the mutational load and PD-L1 expression as biomarkers when selecting a therapeutic approach for your patients. Dr. Ramalingam will also cover the wide range of checkpoint inhibitor targets/immunotherapies and their potential combination with non-immune treatment modalities....

Tumor Immunology: A Primer

2/10/2016
More
Guest: Howard L. Kaufman, MD, FACS Dr. Kaufman will discuss the concepts of tumor immunology, including the cancer-immunity cycle, tumor microenvironment, the targeting the immune system, major approaches to cancer immunotherapy, as well as strategies and approaches to this disease. Dr. Howard L. Kaufman is Chief Surgical Officer and Associate Director for Clinical Sciences at the Rutgers Cancer Institute of New Jersey as well as a Professor in the Department of Surgery, also at Rutgers,...

A Case Review: Treatment-Naïve Patient with Advanced NSCLC

1/26/2016
More
Guest: Everett E. Vokes, MD Guest: Tanguy Y. Seiwert, MD Dr. Everett Vokes and Dr. Tanguy Seiwert share their expertise in NSCLC, reviewing the case of a 55 year old male with no smoking history, treatment-naïve patient with Stage IV non-small cell lung cancer presenting with a cough and hemoptysis. Listen to and view additional case discussions: Treatment-Naïve Patient with Head and Neck Cancer, Treatment-Naïve Patient with Advanced NSCLC: Smoker with Metastatic Squamous Cell Tumor.

The Swiftly Changing Landscape: Multiple Myeloma Trials and Treatments

1/13/2016
More
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG Guest: Robert Z. Orlowski, MD, PhD Guest: Paul G. Richardson, MD With a steadily growing list of therapeutic agents for the treatment of patients with multiple myeloma (MM), hematologist-oncologists are equipped with more therapeutic options in the frontline and salvage settings than ever before. However, this progress brings new challenges. The increasing number of therapeutic agents, the underlying heterogeneity of the disease, and...

An Evolution in Cancer Management: Immune Checkpoint Inhibitors Enhancing Patient Outcomes

12/11/2015
More
Guest: Roy S. Herbst, MD, PhD Recent advances in immunotherapy are changing the standard of care for patients with cancer. Whereas most of the early immune-based approaches were designed to enhance the natural anti-tumor T cell response, these approaches had limited success because the built-in checkpoints that serve to turn off effector T cell responses were preventing the anti-tumor response. What we have gleaned from the past has evolved the way we harness the body’s innate immune...

Hedgehog Pathway Inhibition for Treatment of Basal Cell Carcinoma

11/20/2015
More
Host: Patricia M. LoRusso, DO Host: Aleksandar Sekulic, MD, PhD Host: Vernon K. Sondak, MD Basal cell carcinomas (BCCs) and squamous cell skin cancers are the most common cancers in the United States, with BCC accounting for 80% of all skin cancers. BCC tumors typically appear on sun-exposed skin, are slow growing, and rarely metastasize. BCCs are usually treated with surgery; however, therapies for metastatic and locally advanced BCC have been limited. Until the US Food and Drug...

Inherited Susceptibility to Cancer: What Do Primary Care Providers Need to Know?

10/8/2015
More
Guest: Nicoleta Voian, MD MPH In this presentation, Dr. Nicoleta Voian will be discussing the importance of using a patient’s family history to accurately identify which patients carry an increased risk for cancer and how to refer patients to cancer genetics services at her hospital. She will also review common hereditary cancer syndromes and discuss how to identify the most common red flags in genetics as well as the benefits and limitations of genetic testing. This activity is the first...
See More